These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 1350153)

  • 1. Peptide T in the treatment of severe psoriasis.
    Delfino M; Fabbrocini G; Brunetti B; Procaccini EM; Santoianni P
    Acta Derm Venereol; 1992; 72(1):68-9. PubMed ID: 1350153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide T: a new treatment for psoriasis? A review of our experiences.
    Talme T; Lund-Rosell B; Sundquist KG; Hilliges M; Johansson O; Wetterberg L; Marcusson JA
    Acta Derm Venereol Suppl (Stockh); 1994; 186():76-8. PubMed ID: 8073847
    [No Abstract]   [Full Text] [Related]  

  • 3. Peptide T a new treatment for psoriasis? A study of nine patients.
    Marcusson JA; Talme T; Wetterberg L; Johansson O
    Acta Derm Venereol; 1991; 71(6):479-83. PubMed ID: 1685829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide T improves psoriasis when infused into lesions in nanogram amounts.
    Farber EM; Cohen EN; Trozak DJ; Wilkinson DI
    J Am Acad Dermatol; 1991 Oct; 25(4):658-64. PubMed ID: 1791224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide T and psoriasis.
    Marcusson JA; Lazega D; Pert CB; Ruff MR; Sundquist KG; Wetterberg L
    Acta Derm Venereol Suppl (Stockh); 1989; 146():117-21. PubMed ID: 2609851
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-chemotactic activities of peptide-T: a possible mechanism of actions for its therapeutic effects on psoriasis.
    Raychaudhuri SK; Raychaudhuri SP; Farber EM
    Int J Immunopharmacol; 1998 Nov; 20(11):661-7. PubMed ID: 9848397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin immunoreactive cells in lesional psoriatic human skin during peptide T treatment.
    Johansson O; Hilliges M; Talme T; Marcusson JA; Wetterberg L
    Acta Derm Venereol; 1994 Mar; 74(2):106-9. PubMed ID: 7911613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathological and immunohistochemical changes in psoriatic skin during peptide T treatment.
    Talme T; Rozell BL; Sundqvist KG; Wetterberg L; Marcusson JA
    Arch Dermatol Res; 1995; 287(6):553-7. PubMed ID: 7487141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are CD4 antibodies and peptide T new treatments for psoriasis?
    Poizot-Martin I; Dhiver C; Mawas C; Olive D; Gastaut JA
    Lancet; 1991 Jun; 337(8755):1477. PubMed ID: 1675339
    [No Abstract]   [Full Text] [Related]  

  • 10. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis.
    Höxtermann S; Nüchel C; Altmeyer P
    Dermatology; 1998; 196(2):223-30. PubMed ID: 9568412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide-T in the treatment of psoriasis and psoriatic arthritis. A case report.
    Marcusson JA; Wetterberg L
    Acta Derm Venereol; 1989; 69(1):86-8. PubMed ID: 2563618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic therapy for psoriasis: a brief history, I.
    Tutrone WD; Kagen MH; Barbagallo J; Weinberg JM
    Cutis; 2001 Nov; 68(5):331-6. PubMed ID: 11766118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Quantitative changes in CD4+ and CD8+ T-lymphocytes in the skin of patients with psoriasis treated with cyclosporin A].
    Adamicová K; Fetisovová Z; Cingel P; Péc J; Parobeková K; Chromej I
    Cesk Patol; 2001 Nov; 37(4):154-7. PubMed ID: 11813632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment.
    Heseltine PN; Goodkin K; Atkinson JH; Vitiello B; Rochon J; Heaton RK; Eaton EM; Wilkie FL; Sobel E; Brown SJ; Feaster D; Schneider L; Goldschmidts WL; Stover ES
    Arch Neurol; 1998 Jan; 55(1):41-51. PubMed ID: 9443710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD8+ cell changes in psoriasis associated with roxithromycin-induced clinical improvement.
    Ohshima A; Takigawa M; Tokura Y
    Eur J Dermatol; 2001; 11(5):410-5. PubMed ID: 11525946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Vitamin D Analogue Calcipotriol Reduces the Frequency of CD8+ IL-17+ T Cells in Psoriasis Lesions.
    Dyring-Andersen B; Bonefeld CM; Bzorek M; Løvendorf MB; Lauritsen JP; Skov L; Geisler C
    Scand J Immunol; 2015 Jul; 82(1):84-91. PubMed ID: 25904071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis.
    Ortonne JP
    J Eur Acad Dermatol Venereol; 2003 Jul; 17 Suppl 2():12-6. PubMed ID: 12795770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rearrangement of S-100 immunoreactive Langerhans' cells in human psoriatic skin treated with peptide T.
    Wang L; Hilliges M; Talme T; Marcusson JA; Wetterberg L; Johansson O
    J Dermatol Sci; 1995 Jan; 9(1):20-6. PubMed ID: 7727353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of dipeptidyl-peptidase IV (CD26) on CD8+ T cells is significantly decreased in patients with psoriasis vulgaris and atopic dermatitis.
    Bock O; Kreiselmeyer I; Mrowietz U
    Exp Dermatol; 2001 Dec; 10(6):414-9. PubMed ID: 11737260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective persistence of dermal CD8+ T cells in lesional plaque psoriasis after clobetasol-17 propionate treatment.
    Bovenschen HJ; Vissers WH; Seyger MM; van de Kerkhof PC
    Acta Derm Venereol; 2005; 85(2):113-7. PubMed ID: 15823902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.